Leerink Partners analyst Puneet Souda reiterated a Hold rating on Myriad Genetics (NASDAQ:MYGN) on Friday, setting a price target of $33, which is approximately 28.65% above the present share price of $25.65.
Souda expects Myriad Genetics to post earnings per share (EPS) of -$0.52 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Myriad Genetics, with an average price target of $34.33.
The analysts price targets range from a high of $37 to a low of $33.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $173.1 million and a net profit of -$45.8 million. The company's market cap is $1.98 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.1% and a 48.81% success rate.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.